Novel Rinse to Treat Oral Candidiasis in Cancer Patients

治疗癌症患者口腔念珠菌病的新型漱口水

• 批准号: 6989894
• 负责人: Charles J Gauntt
• 金额: $ 15.95万
• 依托单位: BIOMEDICAL DEVELOPMENT CORPORATION
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-02 至 2006-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6989894
• 关键词: Candida; Candida albicans; antiinfective agents; biofilm; cancer complication; candidiasis; drug adverse effect; drug design /synthesis /production; drug screening /evaluation; laboratory rat; local antiinfective agents; microorganism disease chemotherapy; mouthwash; nonhuman therapy evaluation; opportunistic infections; oral health

DESCRIPTION (provided by applicant): The goal of this project is to develop a unique, safe and efficacious mouth rinse to treat oral candidiasis in patients with cancer. Oral candidiasis or oral thrush is a disease caused by all species of the fungus Candida and is a common infection for immunosuppressed individuals, particularly cancer patients. If not blunted, oral candidiasis can transit to esophageal candidiasis or life-threatening candidemia. The majority of cells of most Candida sp. exist in the oral cavity in a unique ecologic community known as a biofilm. Cells in the encased setting of biofilms are far more resistant to antifungal mouth rinses and drugs than free-living unattached Candida, thus compromising the effectiveness of treatment. In addition, the most effective mouth rinses have several risks and adverse side effects, including induction of potential allergies, exacerbation of periodontitis, increasing tartar on teeth, erosion of enamel and altering of the appreciation for foods. In previous work, Biomedical Development Corporation has developed locide(r), a safe and efficacious broad-spectrum antimicrobial that has been demonstrated to be effective in the presence of biofilm. The objective of this Phase I project is to demonstrate the feasibility of using locide as a mouth rinse for the treatment of oral candidiasis in cancer patients. To achieve this goal, the following Specific Aims will be executed: Specific Aim 1. Optimize locide Formulation for Use in Treating Oral Candidiasis Specific Aim 2. Demonstrate the Effectiveness of locide in Killing Candida albicans and Mixed Candida sp. Cells in Biofilms Specific Aim 3. Demonstrate Safety of locide Formulations

描述（由申请人提供）： 该项目的目标是开发一种独特、安全和有效的漱口水，用于治疗癌症患者的口腔念珠菌病。口腔念珠菌病或口腔鹅口疮是由所有种类的真菌念珠菌引起的疾病，并且是免疫抑制个体，特别是癌症患者的常见感染。如果不钝化，口腔念珠菌病可以转变为食管念珠菌病或危及生命的念珠菌血症。大多数念珠菌属的大多数细胞存在于口腔中的独特生态群落中，称为生物膜。在生物膜包裹的环境中的细胞比自由生活的独立念珠菌对抗真菌漱口水和药物的抵抗力更强，从而影响了治疗的有效性。此外，最有效的漱口水有几个风险和不良副作用，包括诱发潜在的过敏，牙周炎恶化，增加牙齿上的牙垢，牙釉质侵蚀和改变对食物的欣赏。 在以前的工作中，生物医学开发公司已经开发出locide（r），一种安全有效的广谱抗菌剂，已被证明在生物膜存在下有效。该第一阶段项目的目的是证明使用氯杀得作为口腔冲洗剂治疗癌症患者口腔念珠菌病的可行性。为实现这一目标，将执行以下具体目标： 具体目标1.洛杀得治疗口腔念珠菌病处方的优化 具体目标2。证明氯杀灵杀灭生物膜中白色念珠菌和混合念珠菌属细胞的有效性 具体目标3。证明氯杀得制剂的安全性